SLU-PP-332 is a potent synthetic pan-Estrogen-Related Receptor (ERRα/β/γ) small-molecule agonist studied for inducing mitochondrial oxidative phosphorylation, fatty-acid oxidation, and aerobic-exercise transcriptional programs.
Scientific Profile & Research Key Points: SLU-PP-332
SLU-PP-332 is a potent synthetic pan-Estrogen-Related Receptor (ERRα/β/γ) small-molecule agonist studied for inducing mitochondrial oxidative phosphorylation, fatty-acid oxidation, and aerobic-exercise transcriptional programs.
Active Batch Release Specifications (Lot SL-2026-157)
Analytical release verification for current SLU-PP-332 (5 mg) inventory
| Batch Lot # | Release Date | Analytical Method | Purity Spec | Endotoxin (LAL) | Moisture |
|---|---|---|---|---|---|
| SL-2026-157 | 2026-10-28 | HPLC-UV + LC-MS (Small-Molecule Verification) | ≥99.0% (Chromatographic Peak) | <0.5 EU/mg | <2.8% (Karl Fischer) |
Laboratory Solubilization & Storage Protocol
Recommended Solvent / Handling
Sterile DMSO (up to 20–30 mg/mL); insoluble in pure water
Temperature & Stability
Store solid powder at -20°C dry and shielded from light; store DMSO aliquots at -80°C.
SLU-PP-332 — Technical Questions & Answers
What is the molar concentration when reconstituting SLU-PP-332 (5 mg) in 2.0 mL?
Reconstituting the full 5 mg vial of SLU-PP-332 (MW 290.32 g/mol) in 2.0 mL of diluent produces a 2.50 mg/mL stock solution — equivalent to approximately 8.61 mM (8,611 µM) gross molarity before Net Peptide Content (NPC) adjustment.
How does SLU-PP-332's salt form affect assay mass calculations?
SLU-PP-332 (CAS 303760-60-3, formula C18H14N2O2) is supplied as Crystalline free-base small molecule. Because counterions and residual bound water contribute to gross lyophilized weight, quantitative receptor-binding assays should apply batch Net Peptide Content (NPC) or active-ion correction rather than gross cake weight alone.
Which analytical methods verify SLU-PP-332 Lot SL-2026-157 and what pathway does it target?
Lot SL-2026-157 undergoes HPLC-UV + LC-MS (Small-Molecule Verification) confirming ≥99.0% (Chromatographic Peak) and identity against 290.32 g/mol. In preclinical literature, SLU-PP-332 targets Estrogen-Related Receptors ERRα (EC50 98 nM), ERRβ & ERRγ (Billon C. et al., ACS Chem Biol (2023) — Synthetic ERR agonist SLU-PP-332 activates aerobic exercise metabolic programs (PMID: 36988910)).
Related Scientific Monographs
Peer-reviewed mechanism summaries and analytical protocols
SLU-PP-332: Synthetic Pan-ERR Agonist Chemistry, DMSO Solubility & Mitochondrial Biogenesis
Analytical profile of small-molecule pan-ERR agonist SLU-PP-332 (CAS 303760-60-3): nuclear receptor EC50 selectivity, mitochondrial respiration models, and DMSO stock preparation.
Cagrilintide vs Retatrutide: Amylin/Calcitonin Receptors vs Triple Incretin Agonism
Biochemical comparison of long-acting amylin analogue Cagrilintide (AM833) against triple incretin agonist Retatrutide and dual-pathway Cagrilintide + Semaglutide combinations.
Survodutide vs Mazdutide vs Retatrutide: Dual GLP-1/Glucagon and Triple Agonist Biochemistry
Comparative receptor pharmacology of Survodutide (BI 456906), Mazdutide (IBI362), and Retatrutide (LY3437943): GLP-1R/GCGR/GIPR potency ratios and stability.